• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
    • РусскийРусский
  • Menu

THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

06.10.2021/in Publications /by Marketing

Russian pharmaceutical market size in 2016 reached 1,344 billion rubles, which is 7% higher than a year earlier, and in 2017 reached 1,629 billion rubles, which is 8% higher than in 2016.

Drug sales in physical terms increased by 6% to 6.3 billion packs. The positive dynamics in packages in 2017 indicate an improvement in the purchasing power of the population and the reduced impact of financial and economic factors on the pharmaceutical market.

The main contribution to market growth was made by the commercial segment of drugs. The dynamics of

the retail market continued the positive trend of 2016 in packages. Market growth in rubles is lower than in 2016. This was influenced, among other things, by the low incidence of influenza and acute respiratory viral infections, which did not lead to an increase in demand for “seasonal” drugs.

The main two trends in drug consumption are the increase in the share of domestic drugs and consumer switching to generics (generic drug – a drug sold under an international non-proprietary name or a proprietary name different from the brand name of the developer of the drug.

The increase in the commercial drug market in 2018 relative to 2017 in ruble equivalent was 4.6%.

Compared to December 2017, this year the market showed a 6.7% increase in sales. The average cost of drug units in the commercial market of Russia increased by 2.1% in December compared to November and amounted to 197.9 rubles.

The structure of the commercial drug market in December 2018 by price segments has changed in favor of drugs of high price segment compared to the same period of 2017.

The share of the group of drugs under 50 rubles decreased by 0.3% relative to December 2017 and amounted to 4.6%. The share of the segment of drugs with an average package price of 50-150 rubles was 10.3% (-0.3%). The share of the group of drugs with the price range “150-500 rubles” decreased from 46.7% in December 2017 to 44.9% in December 2018. The share of expensive drugs was 40.2%, which is 2.4% higher than the weight of the group in the previous year.

At the end of December 2018. 58.9% of drugs sold on the market were domestic (in physical units), however, due to their low price relative to imported drugs in value terms, they took 29.8%.

The ranking of companies by value sales in December 2018 was headed by Bayer, second place went to Sanofi-Aventis, and third place to Novartis.

The top 3 drug brands by the value of pharmacy sales in Russia in December 2018 consisted of such drugs as Kagocel (1.0%) and Xarelto (0.8%); in third place was Nurofen (0.7%).

The volume of the commercial drug market in January 2019 amounted to 84.3 billion rubles. (in retail prices). Compared to January 2018 this year the market showed an increase in sales by 7.9%.

The structure of the commercial drug market in January 2019 by price segment changed in favor of high price segment drugs compared to the same period of 2018.

The share of the group of drugs under 50 rubles decreased by 0.4% relative to January 2018 and amounted to 4.4%. The share of the segment of drugs with an average package price of 50-150 rubles was 11.3% (-0.4%). The share of the group of drugs with a price range of 150-500 rubles decreased from 44.4% in January 2018 to 43.9% in January 2019. The share of expensive drugs was 40.4%, which is 1.3% higher than in the previous year.

At the end of January 2019. 58.8% of drugs sold on the market were domestic (in physical units), however, due to their low price relative to imported drugs, they took 29.9% in value terms.

The ranking of companies by value sales in January 2019 was headed by Novartis, in second place – Bayer, in third place – Sanofi.

The top 3 among drug brands by pharmacy sales value in Russia in January 2019 consisted of such drugs as Kagocel (1.0%), Inhavirin (0.9%); in third place was Nurofen (0.7%).

 

Sources:

DSM group annual report 2016

DSM group annual report 2017

DSM group annual report 2018

DSM group annual report 2019

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Corrections to clinical trial documents due to COVID-19. Russian experience.
Read More
Publications
WHAT IS BIOEQUIVALENCE
Read More
Publications
THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

4 + 4 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
CLINICAL TRIALS TYPES AND DESIGN WHAT IS BIOEQUIVALENCE
Scroll to top